Article By:
Fred Fuld III
Saturday, February 11, 2023 9:09 PM EDT
CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses.
Editas Medicine, Inc., Announces Pricing Of $50 Million Offering Of Common Stock
Looking forward to hearing more information about $EDIT. Company seems to operate in a very exiting and potentially fast growing new field.